Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
07/28/16Adaptimmune Receives Access to Priority Medicines (PRIME) Regulatory Support for its SPEAR® T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma
New Initiative Provides Access to Scientific Advice and Supports Accelerated Assessment for Therapies Targeting Unmet Medical Needs PHILADELPHIA, Pa. and OXFORD, UK, July 28, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the European Medicines Agency (EMA) has granted access to its newly-established Priority Medicines (PRIME) regulatory initiative for the company’s SPEAR® T-cell therapy targeting NY-ESO fo... 
Printer Friendly Version
07/26/16Adaptimmune Receives Orphan Drug Designation in the European Union for its NY-ESO SPEAR® T-cell Therapy for Treatment of Soft Tissue Sarcoma
PHILADELPHIA and OXFORD, United Kingdom, July 26, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy for treatment of cancer, today announced that the European Commission has designated the company’s NY-ESO SPEAR® T-cell therapy as an orphan medicinal product for the treatment of soft tissue sarcoma, a solid tumor cancer. Adaptimmune previously received orphan drug destination from the U.S. Food and Drug Administration for its NY-ESO SPEAR T-cell... 
Printer Friendly Version
06/21/16Adaptimmune Announces Commercial Development and Supply Agreement for Thermo Fisher Scientific’s Dynabeads™ CD3/CD28 Cell Therapy System
PHILADELPHIA and OXFORD, United Kingdom, June 21, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it has entered into a commercial development and supply agreement with Thermo Fisher Scientific. The new 10-year agreement augments Adaptimmune’s exclusive license and supply relationship with Thermo Fisher for the Dynabeads CD3/CD28 Cell Therapy System (CTS™)* for use in the manufacture of Adaptimmune’s SPEAR™ T... 
Printer Friendly Version
06/20/16Adaptimmune Receives Positive Opinion for Orphan Drug Designation in the European Union for SPEAR™ T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma
PHILADELPHIA and OXFORD, United Kingdom, June 20, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending the company’s SPEAR™ T-cell therapy targeting NY-ESO for designation as an orphan medicinal product for the treatment of soft tissue sarcoma, a solid tumor cancer. Adaptimmune previousl... 
Printer Friendly Version
06/16/16Adaptimmune to Present at the 2016 JMP Life Sciences Conference
PHILADELPHIA and OXFORD, United Kingdom, June 16, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Adrian Rawcliffe, Chief Financial Officer of Adaptimmune, will present at the 2016 JMP Life Sciences Conference on Tuesday, June 21, 2016 at 10:30 AM EDT (3:30 PM BST). The conference is being held at the St. Regis in New York.  Adaptimmune’s presentation will be webcast live for investors through the investor... 
Printer Friendly Version
06/05/16Adaptimmune Announces Data from Clinical Studies of NY-ESO-1 SPEAR™ T-Cells in Multiple Cancers at the 2016 Annual American Society of Clinical Oncology (ASCO) Meeting
PHILADELPHIA and OXFORD, United Kingdom, June 05, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced a poster presentation of updated data on its lead clinical program, an affinity enhanced SPEAR™ T-cell receptor therapy targeting the NY-ESO-1 cancer antigen, in patients with advanced tumors at the 2016 Annual American Society of Clinical Oncology (ASCO) Meeting. Also being presented are an overview of cytokine re... 
Printer Friendly Version
06/02/16Adaptimmune to Present at the Jefferies 2016 Healthcare Conference
PHILADELPHIA and OXFORD, United Kingdom, June 02, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present at the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016 at 4:30 PM EDT (9:30 PM BST). The conference is being held at the Grand Hyatt in New York.  Adaptimmune’s presentation will be webcast live for investors through the investor... 
Printer Friendly Version
05/24/16Adaptimmune Announces Succession Plan for Chairman at End of 2016
PHILADELPHIA and OXFORD, United Kingdom, May 24, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in T-cell therapy to treat cancer, today announced a succession plan for the Chairmanship position that will take effect at the end of 2016. In a planned transition of responsibilities, Chairman, Dr. Jonathan Knowles, will step down from the Board on December 31, 2016. He will be succeeded as Chairman by Mr. David Mott effective from... 
Printer Friendly Version
05/24/16Adaptimmune Strengthens Board with Appointment of Barbara Duncan
PHILADELPHIA and OXFORD, United Kingdom, May 24, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in T-cell therapy to treat cancer, today announced the appointment of Barbara Duncan to its Board of Directors as an independent Non-Executive Director effective from June 23, 2016. Ms. Duncan will also serve as a member of the Audit Committee. “We are delighted that Barbara Duncan has agreed to join our Board of Directors,” commente... 
Printer Friendly Version
05/19/16Adaptimmune to Present at the 2016 UBS Global Healthcare Conference
PHILADELPHIA and OXFORD, United Kingdom, May 19, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present at the 2016 UBS Global Healthcare Conference on Tuesday, May 24, 2016 at 10:30 AM EDT (3:30 PM BST). The conference is being held at the Grand Hyatt in New York.  Adaptimmune’s presentation will be webcast live for investors through the investor ... 
Printer Friendly Version
05/12/16Adaptimmune Reports First Quarter 2016 Financial Results
PHILADELPHIA and OXFORD, United Kingdom, May 12, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in T-cell therapy to treat cancer, today reported financial results for the first quarter ended March 31, 2016. As of March 31, 2016, Adaptimmune had a total liquidity position1 of $226.1 million. The Company is reiterating its cash burn guidance and expects its total liquidity position at December 31, 2016, including cash, cash equi... 
Printer Friendly Version
05/03/16Adaptimmune to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
PHILADELPHIA and OXFORD, United Kingdom, May 03, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that Adrian Rawcliffe, Chief Financial Officer of Adaptimmune, will present at the Bank of America Merrill Lynch 2016 Health Care Conference on Tuesday, May 10, 2016 at 11:20 AM PDT (7:20 PM BST). The conference is being held at the Encore at Wynn, Las Vegas.  Adaptimmune’s presentation will be webcast live for inve... 
Printer Friendly Version
04/27/16Adaptimmune to Present at the Deutsche Bank Securities 41st Annual Health Care Conference
PHILADELPHIA and OXFORD, U.K., April 27, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present at the Deutsche Bank Securities 41st Annual Health Care Conference on Wednesday, May 4, 2016 at 8:40 AM EDT (1:40 PM GMT). The conference is being held at the InterContinental in Boston, MA.  Adaptimmune’s presentation will be w... 
Printer Friendly Version
04/22/16Adaptimmune Presents Corporate and Clinical Updates at Investor and Analyst Day
PHILADELPHIA and OXFORD, United Kingdom, April 22, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today hosted an Investor and Analyst meeting in New York and presented clinical and corporate updates that included progress with pipeline development and manufacturing process optimization. “At today’s event, we were delighted to present an overview of our T-cell therapy and Adaptimmune’s position withi... 
Printer Friendly Version
04/22/16Adaptimmune Announces SPEAR T-cells™ Brand for Proprietary Technology
PHILADELPHIA and OXFORD, United Kingdom, April 22, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the company has adopted the name SPEAR T-cells™ (Specific Peptide Enhanced Affinity Receptor T-cells) to describe its proprietary technology. The SPEAR T-cells brand is intended to symbolize the vital role that Adaptimmune’s enhanced affinity T-cell receptors play in targeting cancer... 
Printer Friendly Version
04/22/16Adaptimmune Appoints Leading Immunotherapy Experts from United States and Europe to Inaugural Scientific Advisory Board
PHILADELPHIA and OXFORD, United Kingdom, April 22, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced the appointment of leading immunology, immunotherapy and oncology experts from across the United States and Europe to its newly formed scientific advisory board (SAB). Crystal Mackall, M.D., Professor of Pediatrics and Medicine and Associate Director of the Stanford Cancer Institute, will se... 
Printer Friendly Version
04/20/16Adaptimmune to Host Analyst and Investor Day on April 22, 2016
PHILADELPHIA and OXFORD, U.K., April 20, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the company will host a live webcast in conjunction with its 2016 Analyst and Investor Day on Friday, April 22, 2016, starting at 8:30a.m. EDT (1:30p.m. BST) in New York, NY The live audio webcast and the accompanying slide presentation will be available at that time through the investor secti... 
Printer Friendly Version
04/18/16Adaptimmune Announces New Vice President of Business Development, Wenyong Wang
PHILADELPHIA and OXFORD, United Kingdom, April 18, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that Dr. Wenyong Wang has joined the company as Vice President of Business Development. Dr. Wang brings substantial experience of licensing, M&A, collaborations, strategic partnerships and business development initiatives with a focus on cancer immunotherapy. Prior to joining Adapti... 
Printer Friendly Version
04/07/16Adaptimmune Announces FDA Acceptance of IND Application for Affinity Enhanced T-Cell Therapy Targeting AFP in Liver Cancer
PHILADELPHIA and OXFORD, United Kingdom, April 07, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s investigational new drug (IND) application for autologous genetically modified T-cells expressing affinity enhanced T-cell receptors (TCRs) specific for alpha fetoprotein (AFP) in patients with locally advanced or me... 
Printer Friendly Version
03/30/16U.S. Food and Drug Administration Grants Orphan Drug Designation to Adaptimmune’s T-cell Therapy Targeting NY-ESO for Treatment of Soft Tissue Sarcoma
PHILADELPHIA and OXFORD, United Kingdom, March 30, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration (FDA)'s Office of Orphan Products Development has granted orphan drug designation for the company’s affinity enhanced T-cell therapy targeting NY-ESO for the treatment of soft tissue sarcoma, a solid tumor cancer. Adaptimmune is developing its NY... 
Printer Friendly Version
03/17/16Adaptimmune Reports Financial Results for the Six-Month Period ended December 31, 2015
PHILADELPHIA and OXFORD, United Kingdom, March 17, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) (“Adaptimmune” or the “Company”), a leader in the use of T-cell therapy to treat cancer, today reported financial results for the six-month period ended December 31, 2015. Adaptimmune previously announced its decision to change its fiscal year end to align fiscal reporting more closely with comparable companies in the industry which use calendar years and to provide more effi... 
Printer Friendly Version
03/02/16Adaptimmune to Present at Cowen and Company’s 36th Annual Health Care Conference
PHILADELPHIA and OXFORD, United Kingdom, March 02, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present at Cowen and Company’s 36th Annual Health Care Conference on Monday, March 7th at 4:40 PM (9:40 PM GMT). The conference is being held at the Boston Marriott Copley Place, in Boston, MA.  Adaptimmune’s presentation will... 
Printer Friendly Version
02/17/16Adaptimmune to Present at the RBC Capital Markets Global Healthcare Conference
PHILADELPHIA, Pa. and OXFORD, United Kingdom, Feb. 17, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present at the 2016 RBC Capital Markets Global Healthcare Conference on Wednesday, February 24 at 11:00 AM ET (4:00 PM GMT). The conference is being held at the New York Palace Hotel in New York, NY.  Adaptimmune’s present... 
Printer Friendly Version
02/09/16U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Adaptimmune’s Affinity Enhanced T-cell Therapy Targeting NY-ESO in Synovial Sarcoma
PHILADELPHIA and OXFORD, United Kingdom, Feb. 09, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation  for the company’s affinity enhanced T-cell therapy targeting NY-ESO in synovial sarcoma for HLA-A*201, HLA-A*205 or HLA-A*206 allele-positive patients with inoperable or metastatic synovial sarcoma ... 
Printer Friendly Version
02/03/16Adaptimmune to Participate in Two Upcoming Investor Conferences  
PHILADELPHIA and OXFORD, United Kingdom, Feb. 03, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that James Noble, Chief Executive Officer of Adaptimmune, will present at the following two conferences, both being held at the Waldorf Astoria in New York City: The 2016 BIO CEO & Investor Conference on Tuesday February 9, 2016 at 9:00AM ET (2:00 PM GMT); and The Leerink Partne... 
Printer Friendly Version
02/02/16Adaptimmune to Host Conference Call at 10:00 AM ET (3:00 PM GMT) Today (Tuesday, February 2) to Discuss Expansion of Strategic Collaboration Agreement with GlaxoSmithKline (GSK)
PHILADELPHIA and OXFORD, United Kingdom, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, will host a live teleconference and webcast at 10:00 a.m. Eastern Time (3:00 p.m. GMT) today (Tuesday February 2, 2016) to discuss the expansion of their strategic collaboration with GSK and the acceleration of the NY-ESO program.   The live webcast of the conference call will be made available via Adapti... 
Printer Friendly Version
02/02/16Adaptimmune and GSK Expand Strategic Immunotherapy Collaboration
Agreement accelerates development of Adaptimmune’s lead T-cell therapy targeting NY-ESO-1 toward pivotal trials Creates opportunity for up to eight combination studies   LONDON, PHILADELPHIA and OXFORD, United Kingdom, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of T- cell receptor (TCR) engineered T-cell therapy to treat cancer, and GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) today announced that the companies have expanded the ter... 
Printer Friendly Version
01/22/16Adaptimmune Announces New Additions to Manufacturing Senior Management
PHILADELPHIA and OXFORD, United Kingdom, Jan. 22, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it has augmented its manufacturing leadership to prepare for clinical and commercial scale up with the additions of William Buecheler as Vice President, Manufacturing Operations, and Phil Bassett as Head of Process Development. Mr. Buecheler is responsible for Adaptimmune's global man... 
Printer Friendly Version
01/07/16Adaptimmune Expands T-cell Engineering Expertise to Develop Affinity Enhanced T-cell Therapies for Autoimmune Indications
PHILADELPHIA and OXFORD, United Kingdom, Jan. 07, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (NASDAQ:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, today announced that it is expanding its T-cell therapy development activities to target certain autoimmune diseases. Professor P. Julian Dyson, Ph.D. has joined the company as the head of the Autoimmune Group with responsibility for leading the autoimmune expansion, including the identification and validati... 
Printer Friendly Version